文献速递白血病造血干细胞移植与细胞治疗

基于塞替派的预处理方案与全身照射作为成人急性淋巴细胞白血病异基因干细胞移植前清髓性预处理的比较:来自欧洲血液与骨髓移植学会急性白血病工作组的配对分析

Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
PubMed 文献 · Am J Hematol · 2017-07-19

该回顾性配对分析比较了成人急性淋巴细胞白血病患者接受基于塞替派的预处理(180例)与环磷酰胺/全身照射(Cy/TBI)预处理(540例)的结局。两组2年无白血病生存率和总生存率相当,移植物抗宿主病发生率无显著差异,但塞替派组复发发生率增高(HR=1.78,95%CI 1.07-2.95,P=.03),未影响总生存。结果提示基于塞替派的预处理对成人ALL患者可能不劣于Cy/TBI。

要点

  • 基于塞替派与Cy/TBI预处理的2年无白血病生存率和总生存率相当。
  • 两组急性和慢性移植物抗宿主病发生率无显著差异。
  • 塞替派组复发发生率增高(HR=1.78,95%CI 1.07-2.95,P=.03),但未影响总生存。

核心结论

  • 基于塞替派的预处理对成人急性淋巴细胞白血病患者可能不劣于环磷酰胺/全身照射预处理。

研究设计与样本

  • 欧洲血液与骨髓移植学会急性白血病工作组的回顾性配对分析,纳入接受基于塞替派预处理(n=180)与环磷酰胺/全身照射预处理(n=540)的成人急性淋巴细胞白血病患者。

主要发现

  • 2年无白血病生存率:塞替派组33%(95%CI 26.4-42.8) vs Cy/TBI组39%(95%CI 34.8-44.5),P=.33。
  • 2年总生存率:塞替派组46.5%(95%CI 38.6-56.1) vs Cy/TBI组48.8%(95%CI 44.2-54),P=.9。
  • 急性和慢性移植物抗宿主病发生率两组间无显著差异。
  • 多因素分析显示塞替派组复发发生率较Cy/TBI组增高(HR=1.78,95%CI 1.07-2.95,P=.03),但未影响总生存。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The optimal conditioning regimen to employ before hematopoietic stem cell transplantation in acute lymphoblastic leukemia (ALL) is still undecided, and while cyclophosphamide/total body irradiation (Cy/TBI) is the most commonly used myeloablative regimen, there are concerns regarding long-term toxicity for patients conditioned with this regimen. Thiotepa-based conditioning is an emerging radiation-free regimen with recent publications indicative of comparable clinical outcomes to TBI-based conditioning. In this analysis of the acute leukemia working party of the EBMT, we performed a retrospective matched-pair analysis, evaluating the outcome of adult patients with ALL who received thiotepa-based conditioning (n = 180) with those receiving Cy/TBI conditioning (n = 540). The 2-year leukemia-free survival and overall survival (OS) rates of both conditioning regimens were comparable, 33% for thiotepa [95% confidence interval (CI): 26.4-42.8] versus 39% for Cy/TBI (95% CI: 34.8-44.5] (P = .33) and 46.5% [95% CI: 38.6-56.1] versus 48.8% [95% CI: 44.2-54] (P = .9), respectively. There was no significant difference between the two regimens in the incidence of either acute graft versus host disease (GVHD) or chronic GVHD. Multivariate analysis demonstrated increased relapse incidence for thiotepa conditioning compared to Cy/TBI (HR = 1.78, 95% CI, 1.07-2.95; P = .03) which did not affect OS. Our results indicate that thiotepa-based conditioning may not be inferior to Cy/TBI for adult patients with ALL.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Eder S, Canaani J, Beohou E, et al. Thiotepa-based conditioning versus total body irradiation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: A matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017. PMID: 28614903. doi:10.1002/ajh.24823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。